[Podcast] A Conversation About Clinical Trials

7 March 2024

No Barriers: A Special Edition of the Parkinson’s Podcast episode summary

This content is made possible through donations made by our listeners.

In this episode, Mark Stacy, MD, and Peter Schmidt, PhD, discuss participation in clinical trials for Parkinson’s. Both speakers have extensive experience designing and implementing clinical trials for Parkinson’s. Dr. Stacy and Dr. Schmidt discuss multiple important topics related to trial participation. For a written overview of clinical trial participation, visit this blog post. 

Want to read the article associated with this podcast? Check it out on our website!

Want to watch the video version of this podcast? You can watch it on our YouTube!

Are you loving the Parkinson’s Podcast? You can listen to more episodes on our website!

Meet the team behind this episode of the parkinson’s podcast

Mark Stacy, MD, a white man with white hair. he is giving a half smile. he is wearing a white lab coat with the MUSC Health logo, a white button-down, and a red tie with blue stripes.Mark Stacy, MD

Associate Professor of Neurology and the Director of the Neuroscience Clinical Research Center, Duke University

Mark Stacy is a Professor of Neurology at the Medical University of South Carolina, a fellow in the American Academy of Neurology, and a board member of WE MOVE. Dr. Stacy has clinical trial experience with and has written extensively about Parkinson’s, dystonia, and tremor and has served on numerous protocol steering committees and safety monitoring boards. His independent research interests include motor and non-motor symptoms of OFF and impulse control disorders in those living with Parkinson’s.

Peter  SchmidT, PhD

Chief Scientific Officer at RhoPeter Schmidt, PhD. He has a half smile, a white face, a balding head with black hair, a black suit, a white button-down, and a blue tie.

Peter Schmidt, PhD, is the Chief Scientific Officer at Rho. From 2009 through April, 2018, Dr. Schmidt served as Senior Vice President and Chief Research and Clinical Officer at the Parkinson’s Foundation where he oversaw research, education, and outreach initiatives. Through his tenure at the Parkinson’s Foundation, Dr. Schmidt served as PI for the Parkinson’s Outcomes Project (POP) from launch through the 10,000th subject recruited, the largest clinical study ever in Parkinson’s conducted at 30 academic medical centers. The Parkinson’s Outcomes Project was designed to identify best practices in Parkinson’s care but served as a platform for many other studies.
Dr. Schmidt is active in research, specializing in the intersection between mathematics and medicine, with a special interest in mapping the n-dimensional spaces of clinical data. Schmidt serves as an advisor to several government, industry, and foundation initiatives. He has been involved in several national-scale quality initiatives, including with the US National Quality Forum and the Fresco Network in Italy. Schmidt has recent or current advisory engagements in wearable sensors, telemedicine and remote monitoring, and clinical trial design. He has contributed to AHRQ and Commonwealth Fund publications and has been an invited speaker for NIH and diverse international patient and professional conferences. Schmidt previously worked in corporate finance focused on healthcare innovation, created chronic disease management systems, and served as Chief Operating Officer of a joint venture of Oxford, Stanford, and Yale delivering online education. Educated at Harvard and Cornell, he had a fellowship at New York’s Hospital for Special Surgery.

 

LISTEN TO THE EPISODE

follow us

@media screen and (max-width: 1023px) {.thegem-vc-text.thegem-custom-65e914664524b7179{display: block!important;}}@media screen and (max-width: 767px) {.thegem-vc-text.thegem-custom-65e914664524b7179{display: block!important;}}@media screen and (max-width: 1023px) {.thegem-vc-text.thegem-custom-65e914664524b7179{position: relative !important;}}@media screen and (max-width: 767px) {.thegem-vc-text.thegem-custom-65e914664524b7179{position: relative !important;}}

@media screen and (max-width: 1023px) {.thegem-vc-text.thegem-custom-65e9146645d855823{display: block!important;}}@media screen and (max-width: 767px) {.thegem-vc-text.thegem-custom-65e9146645d855823{display: block!important;}}@media screen and (max-width: 1023px) {.thegem-vc-text.thegem-custom-65e9146645d855823{position: relative !important;}}@media screen and (max-width: 767px) {.thegem-vc-text.thegem-custom-65e9146645d855823{position: relative !important;}}

@media screen and (max-width: 1023px) {.thegem-vc-text.thegem-custom-65e91466460c01216{display: block!important;}}@media screen and (max-width: 767px) {.thegem-vc-text.thegem-custom-65e91466460c01216{display: block!important;}}@media screen and (max-width: 1023px) {.thegem-vc-text.thegem-custom-65e91466460c01216{position: relative !important;}}@media screen and (max-width: 767px) {.thegem-vc-text.thegem-custom-65e91466460c01216{position: relative !important;}}

@media screen and (max-width: 1023px) {.thegem-vc-text.thegem-custom-65e91466463de4359{display: block!important;}}@media screen and (max-width: 767px) {.thegem-vc-text.thegem-custom-65e91466463de4359{display: block!important;}}@media screen and (max-width: 1023px) {.thegem-vc-text.thegem-custom-65e91466463de4359{position: relative !important;}}@media screen and (max-width: 767px) {.thegem-vc-text.thegem-custom-65e91466463de4359{position: relative !important;}}

@media screen and (max-width: 1023px) {.thegem-vc-text.thegem-custom-65e91466467aa7363{display: block!important;}}@media screen and (max-width: 767px) {.thegem-vc-text.thegem-custom-65e91466467aa7363{display: block!important;}}@media screen and (max-width: 1023px) {.thegem-vc-text.thegem-custom-65e91466467aa7363{position: relative !important;}}@media screen and (max-width: 767px) {.thegem-vc-text.thegem-custom-65e91466467aa7363{position: relative !important;}}

@media screen and (max-width: 1023px) {.thegem-vc-text.thegem-custom-65e9146646c753976{display: block!important;}}@media screen and (max-width: 767px) {.thegem-vc-text.thegem-custom-65e9146646c753976{display: block!important;}}@media screen and (max-width: 1023px) {.thegem-vc-text.thegem-custom-65e9146646c753976{position: relative !important;}}@media screen and (max-width: 767px) {.thegem-vc-text.thegem-custom-65e9146646c753976{position: relative !important;}}

The post [Podcast] A Conversation About Clinical Trials appeared first on Davis Phinney Foundation.

#Parkinsons

Posted at Davis Phinney

#Shuffles

Davis Phinney - Parkinsons

Categories

0 Comments

Submit a Comment

Parkinsons, Odd behaviour and Medications

Parkinsons, Odd behaviour and Medications

Do you have a friend or loved one with Parkinsons ? You reckon that would be bad enough ? Is their behaviour a bit (or a lot or even dangerously) out of character? It may be the drugs they are taking and not their real self or the disease!Please read ALL of this post...

Introduction and Excuse me!

Introduction and Excuse me!

Pardon me, while I get this social media enterprise working. It has taken me 12 months to get this far with this editorial labyrinth. My former pre Parkinson’s self would have had this whipped up in a week or two, reality changes ability, however I won’t let it kill...

They Call me Shuffles

They Call me Shuffles

    A diagnosis with Parkinson's changes a lot of things: Motor function, non-motor functions, but maybe even more powerful is the changes in social interactions. I personally don't mind being called "Shuffles" now, I did at first (8 or so years ago I think), I...